Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
129
resultados
Última actualización
11/06/2026 [07:42:00]
Resumen de: US20260152808A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: WO2026115801A1
Provided is an inflammatory bowel disease testing method. This inflammatory bowel disease testing method comprises (1) a step for detecting biomarkers in a biological sample collected from a subject. The biomarkers include: proHp and LRG; or proHp and CRP.
Resumen de: WO2026115199A1
The present invention is related to a method for determining or confirming inflammatory bowel disease (IBD) in a subject, the method comprising detecting the amount of keratin 18 (K18) and/or keratin 19 (K19) mRNA or protein in a biological sample obtained from said subject. The present method can also be used for differentiating microscopic colitis from IBD.
Resumen de: US20260153518A1
0000 A method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
Resumen de: CN118581207A
The invention provides a marker for diagnosing systemic inflammation and application, the marker comprises ADGRE3mRNA or ADGRE3 protein, or ADGRE3mRNA fragment and ADGRE3 protein fragment, the marker content in samples of systemic inflammation patients and healthy people has significant difference, clinical verification shows that the marker is high in diagnosis sensitivity and specificity, and the marker can be applied to diagnosis of systemic inflammation. Therefore, systemic inflammation can be accurately diagnosed by detecting the transcription level of ADGRE3 mRNA or the expression level of ADGRE3 protein in an individual sample. Compared with an existing inflammation marker, the ADGRE3 mRNA and the ADGRE3 protein have higher sensitivity and specificity in the aspect of diagnosis of systemic inflammation.
Resumen de: US20260146996A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin ανβ6 in a specimen.
Resumen de: WO2016167365A1
Provided is a marker for determining a mental disease, which can be used for an objective diagnosis of a mental disease. A marker for determining a metal disease, which comprises at least one enterobacterium selected from those belonging to Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens and Enterobacteriaceae.
Resumen de: US20260142011A1
Provided herein are systems and methods for optimizing a biological therapy regimen for a subject. The subject may be a patient diagnosed with an immune mediated inflammatory disease. In some embodiments, the systems and methods may involve inputting patient data into a model to forecast a drug concentration level in a patient and establish a dosing regimen for maintaining a pre-specified threshold drug concentration level in the patient. The pre-specified threshold may be a target concentration level for effective treatment of the immune mediated inflammatory disease in the patient.
Resumen de: US20260140112A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be selected from a hinge region of Lachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.
Resumen de: EP4744731A2
0001 The present invention relates to an antibody for treating or preventing autoimmune diseases. The antibody of the present invention comprises a heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region set forth in SEQ ID NO: 6.
Resumen de: EP4745571A1
0001 A method for determining a mucosal disorder in a gastrointestinal tract includes: a preparation step for preparing a biological sample collected from a subject to which an endoscopic dye compound has been administered; a measurement step for measuring an amount of the endoscopic dye compound or a metabolite thereof in the biological sample; a comparison step for comparing the measured amount of the endoscopic dye compound or a metabolite thereof with a reference value; and a determination step for determining that the subject is highly likely to have a mucosal disorder in the gastrointestinal tract if the measured amount of the endoscopic dye compound or a metabolite thereof is equal to or greater than the reference value.
Resumen de: KR20240124203A
The present invention relates to a companion diagnostic biomarker composition for predicting an astragalin treatment response to inflammatory bowel disease. By confirming that the expression of stathmin or regulator of chromosome condensation 2 (RCC2) is specifically reduced in a response group having an astragalin treatment response to inflammatory bowel disease, the present invention can be used as the companion diagnostic biomarker composition for predicting an astragalin treatment response to inflammatory bowel disease.
Resumen de: WO2026097001A2
The present disclosure is related to ex vivo methods and devices for identifying a presence of or predicting a risk for a condition in a subject, wherein the risk or condition is correlated with an oxidation-redox potential (ORP) of a biological sample obtained from the subject, such as a fecal sample. The methods and devices of the present disclosure can be used to diagnose and monitor gut microbiome health and assess the risk and/or presence of conditions such as obesity, metabolic dysfunction associated steatotic liver disease (MASLD), type 2 diabetes, hyperlipidemia, hypertension, cardiovascular disease, a gut specific condition, irritable bowel syndrome, an inflammatory bowel disease, ulcerative colitis, Crohn's disease, a Clostridium difficile infection, or any combination thereof based on an ORP of the subject's sample.
Resumen de: WO2025003436A1
The present application provides an ultrasensitive colorimetric assay as well as an early biomarker for patient monitoring and medical treatment of patients suffering from a possible mitochondrial dysfunction, inflammatory bowel disease, particularly Crohn's disease. The ultrasensitive colorimetric assay measures the level of L-citrulline in a plasma or serum sample; and when the level of L-citrulline in plasma or serum decreases or falls even below 30 µmol L-citrulline, this indicates a mitochondrial cell disorder caused by a relapse or an increase in intestinal inflammation due to a flare of Crohn's disease. A method of detecting and treating the mitochondrial dysfunction is also provided.
Resumen de: US20260114804A1
0000 Disclosed herein, in some aspects, are systems and methods for determining and/or monitoring a stool condition for a subject. In some embodiments, the stool condition is based on one or more images of stool of a subject. In some embodiments, the stool condition correlates with a stool assessment comprising i) a characterization of the stool according to a plurality of characteristics, and/or ii) identifying one or more medical conditions, illnesses, and/or diseases associated with the stool. In some embodiments, the stool condition is determined using one or more Artificial Intelligence engines using a trained data set. In some embodiments, the stool condition is based on one or more stool assessments performed for one or more stools corresponding to one or more bowel movements over a period of time.
Resumen de: AU2024354463A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: AU2024362918A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Resumen de: CN121930341A
本发明提供了TL1A结合分子及其应用。具体地，本发明提供了抗TL1A单域抗体或其抗原结合片段，其能够与人和食蟹猴TL1A结合，阻断TL1A/DR3通路，但不影响TL1A与TL1A/DR3通路的天然阻断剂DcR3的结合。本发明的抗TL1A单域抗体或其抗原结合片段与TL1A的结合具有pH依赖性，更有利于在体内长期循环，延长半衰期。因此，本发明的抗TL1A单域抗体或其抗原结合片段可作为新型治疗剂，应用于免疫炎症相关疾病的治疗。
Resumen de: US20260109755A1
0000 The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.
Resumen de: WO2026080407A1
Provided herein are methods and systems for detection of precancer or cancer. The method may comprise using cell-free nucleic acids. The methods may comprise assaying nucleic acids. The method may comprise extracting cell-free nucleic acids. The methods may comprise generating libraries based at least on cell-free nucleic acids.
Resumen de: CN121831162A
本发明涉及分子诊断技术领域，公开了一种炎症性肠病诊断用细胞外囊泡蛋白质标志物及应用，该标志物源于血浆细胞外囊泡膜蛋白，包括用于诊断克罗恩病的组分I、诊断溃疡性结肠炎的组分II及鉴别用的组分III。本发明采用聚合物沉淀结合超速离心法提取囊泡，利用抗体寡核苷酸偶联探针及邻近条形码分析技术进行高通量检测。结合机器学习算法对囊泡亚群进行聚类分析，应用该标志物制备的试剂盒，通过检测特定蛋白组合及细胞外囊泡亚群比例，实现了炎症性肠病的无创筛查、早期诊断及亚型精准鉴别，有效解决了现有单一标志物诊断盲区与个体异质性问题，具有高灵敏度、高特异性及非侵入性优势。
Resumen de: KR20260045660A
본 발명은 크론병 환자 십이지장 오가노이드 유래 장 상피 단층 모델의 분화 방법에 관한 것으로, 발명의 장 상피 단층 모델은 3차원 십이지장 오가노이드로부터 해리된 단일 세포에 기초하여 분화를 유도한 것으로, 다양한 장 상피 세포 유형을 포함하고 내강(lumen)에 대한 접근성을 제공한다. 또한, 본 모델은 실제 환자 장 점막의 구조와 기능을 효과적으로 모사할 수 있어 염증성 장질환을 포함한 다양한 장 질환의 병태생리 연구뿐만 아니라, 후보 물질의 효능 및 안전성을 평가하는 데 유용하게 활용될 수 있다.
Resumen de: WO2026064841A1
The present invention relates in part to methods of detecting Mycobacterium avium subsp. paratuberculosis in ruminant animals and markers for use in such methods.
Resumen de: WO2026072849A2
The present disclosure provides pharmaceutical compositions, dosage forms comprising the pharmaceutical composition, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, and treating colorectal cancer in a subject in need thereof, comprising administering the pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof.
Nº publicación: AU2026201512A1 02/04/2026
Solicitante:
SMARTDNA PTY LTD
smartDNA Pty Ltd
Resumen de: AU2026201512A1
The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS). eb e b
BOPI
Sede Electrónica
